154 related articles for article (PubMed ID: 35297203)
1. A novel nano-immunotherapeutic remodels the immune landscape of malignant pleural effusion: Insights into its mechanism of action through single-cell RNA-sequencing.
Liu Y; Zhao D
Clin Transl Med; 2022 Mar; 12(3):e774. PubMed ID: 35297203
[TBL] [Abstract][Full Text] [Related]
2. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion.
Liu Y; Wang L; Song Q; Ali M; Crowe WN; Kucera GL; Hawkins GA; Soker S; Thomas KW; Miller LD; Lu Y; Bellinger CR; Zhang W; Habib AA; Petty WJ; Zhao D
Nat Nanotechnol; 2022 Feb; 17(2):206-216. PubMed ID: 34916656
[TBL] [Abstract][Full Text] [Related]
3. Translational Nanotherapeutics Reprograms Immune Microenvironment in Malignant Pleural Effusion of Lung Adenocarcinoma.
Song Z; Luo W; Zheng H; Zeng Y; Wang J; Chen T
Adv Healthc Mater; 2021 Jun; 10(12):e2100149. PubMed ID: 33870649
[TBL] [Abstract][Full Text] [Related]
4. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
Li X; Wu G; Chen C; Zhao Y; Zhu S; Song X; Yin J; Lv T; Song Y
Front Immunol; 2021; 12():760683. PubMed ID: 34966384
[TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals immune microenvironment of small cell lung cancer-associated malignant pleural effusion.
Wang S; An J; Hu X; Zeng T; Li P; Qin J; Shen Y; Chen M; Wen F
Thorac Cancer; 2024 Jan; 15(1):98-103. PubMed ID: 38010064
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients.
Zhang Z; Ji W; Huang J; Zhang Y; Zhou Y; Zhang J; Dong Y; Yuan T; Yang Q; Ding X; Tang L; Li H; Yin J; Wang Y; Ji T; Fei J; Zhang B; Chen P; Hu H
Clin Transl Med; 2022 Nov; 12(11):e1072. PubMed ID: 36305631
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into the systemic treatment of lung cancer malignant pleural effusion.
Tissot C; Gay P; Brun C; Froudarakis ME
Clin Respir J; 2019 Mar; 13(3):131-138. PubMed ID: 30737898
[TBL] [Abstract][Full Text] [Related]
8. C1q
Zhang S; Peng W; Wang H; Xiang X; Ye L; Wei X; Wang Z; Xue Q; Chen L; Su Y; Zhou Q
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604643
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.
Tseng YH; Ho HL; Lai CR; Luo YH; Tseng YC; Whang-Peng J; Lin YH; Chou TY; Chen YM
J Thorac Oncol; 2018 Mar; 13(3):447-453. PubMed ID: 29246835
[TBL] [Abstract][Full Text] [Related]
10. Mutant KRAS promotes malignant pleural effusion formation.
Agalioti T; Giannou AD; Krontira AC; Kanellakis NI; Kati D; Vreka M; Pepe M; Spella M; Lilis I; Zazara DE; Nikolouli E; Spiropoulou N; Papadakis A; Papadia K; Voulgaridis A; Harokopos V; Stamou P; Meiners S; Eickelberg O; Snyder LA; Antimisiaris SG; Kardamakis D; Psallidas I; Marazioti A; Stathopoulos GT
Nat Commun; 2017 May; 8():15205. PubMed ID: 28508873
[TBL] [Abstract][Full Text] [Related]
11. Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients.
Bruschini S; Pallocca M; Sperandio E; D'Ambrosio L; Ascenzi F; De Vitis C; Salvati V; Esposito A; Di Martino S; De Nicola F; Paolini F; Fattore L; Alessandrini G; Facciolo F; Foddai ML; Bassi M; Venuta F; D'Ascanio M; Ricci A; D' Andrilli A; Napoli C; Aurisicchio L; Fanciulli M; Rendina EA; Ciliberto G; Mancini R
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584864
[TBL] [Abstract][Full Text] [Related]
12. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion.
Wang D; Yang L; Yue D; Cao L; Li L; Wang D; Ping Y; Shen Z; Zheng Y; Wang L; Zhang Y
Cancer Lett; 2019 Jun; 452():244-253. PubMed ID: 30928379
[TBL] [Abstract][Full Text] [Related]
15. Microarray expression profile and analysis of circular RNA regulatory network in malignant pleural effusion.
Wen Y; Wang Y; Xing Z; Liu Z; Hou Z
Cell Cycle; 2018; 17(24):2819-2832. PubMed ID: 30563416
[TBL] [Abstract][Full Text] [Related]
16. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
17. Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.
Lee PH; Yang TY; Chen KC; Huang YH; Tseng JS; Hsu KH; Wu YC; Liu KJ; Chang GC
Sci Rep; 2021 Apr; 11(1):9381. PubMed ID: 33931705
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
19. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
[TBL] [Abstract][Full Text] [Related]
20. Mast cells mediate malignant pleural effusion formation.
Giannou AD; Marazioti A; Spella M; Kanellakis NI; Apostolopoulou H; Psallidas I; Prijovich ZM; Vreka M; Zazara DE; Lilis I; Papaleonidopoulos V; Kairi CA; Patmanidi AL; Giopanou I; Spiropoulou N; Harokopos V; Aidinis V; Spyratos D; Teliousi S; Papadaki H; Taraviras S; Snyder LA; Eickelberg O; Kardamakis D; Iwakura Y; Feyerabend TB; Rodewald HR; Kalomenidis I; Blackwell TS; Agalioti T; Stathopoulos GT
J Clin Invest; 2015 Jun; 125(6):2317-34. PubMed ID: 25915587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
